Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3

Recruiting now

Conditions studied: Alpha-Mannosidosis

In brief

The goal of this observational study is to learn the effects of the drug velmanase alfa (Lamzede®) in the bodies of children under the age of 3 with Alpha-Mannosidosis. The main questions it aims to answer are: * study the effect of velmanase alfa on a marker of the disease called GlcNAc(Man)2 after one year of therapy * explore how the child's body reacts to velmanase alfa during the therapy The parents or legal guardians of participants will be asked to provide the results of analyses performed in the routine clinical setting related to the participant's general health and the administration of velmanase alfa. Additional data will be extracted from other observational sponsored studies/registries, compassionate use programs, investigator-initiated studies (IIS), and published case reports (presented in the literature) if existing.

Key facts

Study ID

NCT06184503

Run by

Chiesi Farmaceutici S.p.A.

People needed

5

Starts

2025-02-19

Expected to finish

2029-09-01

Last updated by the study team

2025-05-16

Who can join

Age: any, up to 3. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with the provision of informed consent from their legal guardians (LAR)
• Have a confirmed diagnosis of alpha mannosidosis
• Have initiated treatment with velmanase alfa between birth to at least six weeks before turning 3 years of age
• Have information on the disease marker GlcNAc(Man)2 obtained:
• before velmanase treatment initiation (ideally max 6 month before), and at least one post-treatment sample, collected following at least six weeks of treatment.
• Participants treated with Lamzede, 1 mg/kg body weight, via weekly intravenous infusions.

You may not qualify if…

• Participants who have undergone prior hematopoietic stem cell transplantation (HSCT) or other investigational therapies for treating alfa mannosidosis (supportive treatments acceptable).

Where it is running

• Nicklaus Children's Hospital — Miami, Florida, United States (enrolling)
• Greenwood Genetic Center — Greenwood, South Carolina, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.